department of internal medicine - unmc | home

Department of Internal Medicine

Inside this issue:

Campbell Receives First IHTSDO Award for Excellence

Dr. James Campbell, professor, General Internal Medicine Section, was hon-ored as the first recipient of the Award for Excellence given by the International Health Terminology Standards Development Organisation (IHTSDO) at the General Assembly in Helsingør, Denmark, in April. IHTSDO is a not-for-profit association that develops and promotes the use of the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED CT) to support global efforts for a common health terminol-ogy. SNOMED CT is a clinical terminology that is considered to be the most comprehen-sive, multilingual healthcare terminology in the world.

IHTSDO Award 1

From the Chair 1

Honors & Awards 2

Research Briefs 5

In the News - Dr. Robert Grissom

8

Education Highlights 9

Faculty Grants 10

Faculty Publications 14

This issue of the departmental newsletter again emphasizes the significant academic activities of our faculty and the awards they continue to garner. Through the faculty, the department continues to expand its national and international reputation as evidenced by the awards and grants that we have received. I invite you to review this newsletter and congratulate those who have achieved significant accomplishments that are recognized at international, national, regional and local levels.

It is appropriate for us to spend some time in reflection in honoring the life of Bob Grissom, who passed away in March. To a very real extent, the very nature of the current department was established by Dr. Grissom, as he was the first full-time chair. As chairman, Dr. Grissom established the principle of demanding much from his faculty, from his students and from his residents. He, in turn, gave much, constantly putting the patient first and always conducting himself with the highest level of professionalism. Dr. Grissom consistently remained an active and supportive member of the department. We all recall his coming to Grand Rounds even during the last weeks of his life, modeling what a lifelong learner and an as-tute physician is all about. I personally will miss Bob's cheerful greetings and his constant smile. We can best honor Bob by always conducting ourselves in a dig-nified and professional manner as we seek to put our patients first in all of our activities. Dr. Lynell Klassen

Message From The Chair . . .

Continued on page 2

Internal Medicine Newsletter - May 2009

Several colleagues in IHTSDO’s global community nominated Dr. Campbell. According to his nominators, Campbell was a proponent of the use of a common health terminology and SNOMED CT even prior to the creation of IHTSDO. He demonstrated the implementation of SNOMED CT in his daily medical practice. His years of experience working with SNOMED CT implementations and associated mappings (linking the terms of different systems to extract information for multiple purposes) have proven to be an invaluable contribution to the group, nominators said.

His nominators also praised him for his lead-ership and tireless effort in launching IHTSDO’s Mapping Special Interest Group (SIG). Accord-ing to them, his group was very rapidly able to advance the mission of the organization in their efforts related to adoption and harmonization. SIG was comprised of a globally diverse group of members that became a cohesive committee focused on the SNOMED CT to ICD 10, the World Health Organization-endorsed Interna-tional Classification of Diseases 10, mapping. This effort resulted in a full project plan for the ICD 10 mapping

Campbell Receives First IHTSDO Award for Excellence (Continued from page 1)

Honors and Awards . . .

Rennard Receives ORCA

The Outstanding Re-search and Creative Activ-ity Awards (ORCA) are given annually to two fac-ulty members within the University of Nebraska system in recognition of their outstanding research or creative activity of na-tional or international sig-nificance. Dr. Stephen Rennard, Larson Profes-sor of Medicine, of the Pul-

monary, Critical Care, Sleep and Allergy Medi-cine Section, was one of the 2009 recipients of this award.

His nominator, Dr. Tom Rosenquist, called him the “best of the best,” in part due to his com-passion, curiosity, and desire to challenge and ad-vance knowledge. Dr. Rennard was also honored for his research endeavors in 2006 by the Univer-sity of Nebraska Medical Center as the first Scien-tist Laureate.

As a pulmonary and critical care physician, Dr. Rennard would like to cure the incurable, ac-cording to a 2007 interview in UNMC Today. He

realizes that it is difficult for patients to accept the limitations for cure due to conditions of chronic obstructive pulmonary disease, and he wants more for his patients. Rennard has worked to help them in many ways: through innovative approaches to research in mecha-nisms of lung injury, inflammatory airway dis-ease, fibrosis and lung stem cell biology, and in clinical care of COPD, asthma, bronchitis and smoking cessation.

He has testified before the Omaha City Council on the hazards of secondhand smoke and lobbied in Omaha for a smoking ban in pub-lic places since he first arrived in Nebraska. He has authored more than 300 articles and 250 chapters on airway disease and smoking cessa-tion and was the lead author for the smoking ces-sation section of the COPD guidelines of the American Thoracic Society.

Dr. Rennard maintains a large laboratory with approximately 17 employees and students, and has mentored more than 25 visiting scientists who come from abroad. He is supported by ap-proximately $4 million in funding from various grants and contracts.


Honors and Awards continued. . .

Thomas Porter, MD, pro-fessor and Hubbard Chair of Cardiology and director of the Cardiac Imaging Program, has an international reputation for his innovative research in the area of cardiac microbubbles for imaging and therapeutics. He uses microbubbles to view heart chambers and heart mus-cles with therapeutic ultra-

sound. Dr. Porter has demonstrated in experimen-tal models that microbubbles can be used to target and deliver therapeutic agents to the sites of coro-nary artery inflammation and he hopes to improve on methods for the treatment of heart attacks and stroke through use of less invasive methods.

Dr. Porter has been the principal investigator on 34 extramural grants or contracts. He holds 18 patents. He has authored or co-authored over 130 articles in peer reviewed journals and 19 book chapters. He has given over 120 invited lectures. He’s held many positions with national organiza-tions including the American Society of Echocardi-ography, the American College of Cardiology and the American Heart Association. He has also been a reviewer for several prestigious cardiology-related journals. Dr. Porter believed there was an increased risk of death for patients using contrast agents and was able to convince the FDA to revise recommendations regarding recovery time for pa-tients who receive contrast agents as part of their diagnostic procedure.

As a physician/scientist, Dr. Porter believes success should be measured in how the research you do improves patient health care.

UNMC Distinguished Scientists

Julie Vose, MD, professor and N/M Harris Oncology Pro-fessor; chief, Hematology/Oncology Section; and associate director of clinical research in the Eppley Cancer Institute has conducted research on lym-phoma since she was a medical student at UNMC. Her research focuses on clinical and transla-tional research in novel thera-

pies and methodologies for the treatment of lympho-mas.

She has authored or co-authored 254 articles published in peer reviewed journals and 38 book chapters. She is frequently an invited speaker at various professional meetings and has given 255 presentations nationally and internationally. She has been an invited reviewer for prestigious journals like The New England Journal of Medicine, Annals of Internal Medicine and the Journal of Clinical Oncol-ogy and frequently serves as an NIH grant reviewer. She has organized local, national, and international training programs for physicians of all levels. She is PI on 35 active grants or contracts and co-directs the Nebraska Lymphoma Study Group, which is respon-sible for large amounts of data used for research on the diagnosis and treatment of lymphoma.

Dr. Vose said she enjoys discovering new thera-pies that work to treat patients and understanding why new therapies work on specific types of lym-phoma. For Dr. Vose, the ultimate success is help-ing patients get back to a normal life, free of lymphoma.

Dr. Thomas Porter and Dr. Julie Vose were among the 23 researchers named as 2008 UNMC Distinguished Scientists.

"Each year, it is a pleasure to have the opportunity to consider nominees for the UNMC Distinguished Scientist and New Investigator awards," Tom Rosenquist, Ph.D., vice chancellor for research said. "It is a rewarding exercise to review our corps of outstanding scientists and see their accomplishments. This year's class is typical: top researchers from a variety of disciplines and backgrounds, publishing their work in the best journals and competing successfully at the highest levels for research grants.”

As part of the recognition, UNMC Today highlights each investigator and asks them questions about the pursuit of their research career. Following are some of the highlights and accomplishments of the Internal Medicine recipients for 2008.


Honors and Awards continued. . .

Jennifer Larsen, MD, associate dean for clinical research, professor and section chief, Diabe-tes, Endocrinology, and Metabolism and Louise and Morton Degen Professor of Internal Medi-cine, was elected to a three year term as a councilor on the Executive Council of the Endocrine Society, the largest professional society of endocrinologists in the United States. She currently serves as the chair of the Planning Committee for the Endocrine Society's annual Continuing Medical Education Symposium and as a member of the Science and Education Committee, which approves and coordinates all educational programs of the Endocrine Society.

Sussana Von Essen, MD, MPH, professor, Pulmonary, Critical Care, Sleep & Allergy Medicine Section, was the recipient of the Robert D. Sparks, M.D. Award in Public Health, an award given by the College of Public Health in recognition of contributions and leadership in the field of public health. Dr. Von Essen was honored for her history of accomplishments that demonstrate a measurable impact on the advancement of effective public health approaches and her commitment to excellence and collaboration.

Jennifer Parker, MD, assistant professor of medicine and pediatrics, received the UNMC Outstanding Teaching Award for the 2008-2009 academic year. She has been a weekly lec-turer for the junior internal medicine clerkship and also teaches the EKG portion of the clerk-ship. Dr. David O’Dell said she excels in both of these areas. Dr. Parker is one of the three physicians who replaced Dr. LeeRoy Meyer, the legendary UNMC teacher/physician, after his death in 2005. Dr. Parker and the other instructors of the clerkship follow in Dr. Meyer’s foot-steps using the Socratic method. This forces the students to be prepared during a lecture since

the instructors stop and ask questions of the students as they go. It is a little more work for the instructors, however. According to Dr. O’Dell, the students love Dr. Parker’s style. She said she appreciates humor and likes to keep the environment light.

Mark Rupp, MD, professor in the Infectious Diseases Section began a one year term as presi-dent of the Society for Healthcare Epidemiology of America (SHEA) on January 1, 2009. SHEA is a worldwide organization with nearly 1,500 members in all branches of medicine, public health and health care epidemiology. Dr. Rupp said SHEA is well respected and valued for its opinion on issues regarding health care-associated infections and the prevention of spreading antimicrobial-resistant pathogens. SHEA hopes to assist the new federal admini-

stration in shaping health care policy in the area of health care-related infections.

Drs. James Armitage, Philip Bierman, Michael Sorrell and Julie Vose were listed among those named in Castle Connolly’s “America’s Top Doctors,” the 18th edition.

Julie Vose, MD, was elected to serve another five year term on the Lymphoma Research Foun-dation’s Scientific Advisory Board. The foundation is an international foundation that raises awareness and funding to further lymphoma research and patient care.

Catherine Eberle, MD, associate professor, Geriatrics/Gerontology Section, was selected by the Nebraska Hospice and Palliative Care Partnership (NHPCP) as one of their annual recipi-ents of the Shining Star awards. NHPCP’s mission is to improve care and conditions for chroni-cally and terminally ill Nebraskans. Dr. Eberle was recognized for her significant contribution and outstanding leadership in the promotion of end-of-life service, education and program development.


changes in gene networks responsible for controlling these behaviors. They only saw changes in gene networks that control immune function. Dr. Bonasera will continue further work in this area with support from an RO1 when NIH receives the letter of relinquishment from his former insti-tution, UCSF.

In order to transition from the ba-sic science model to helping a clini-

cally relevant population, Bonasera is collaborat-ing with other departments at UNMC, UNO, and UCSF to collect similar patient information to that which was collected on mice. It is much more challenging with a human population Dr. Bonasera said. Whatever method is used must be very non-invasive, non-intrusive and simple to use. Using an activity watch and a user-friendly cell phone, they can collect data showing how people organize their day-to-day activities and patterns. This system is nice because it uses off-the-shelf technology that is fairly inexpensive. This research project is currently supported from Oldfield Foundation funds.

Dr. Bonasera sees the potential for this sys-tem being used as a tool to assess people prior to major procedures like surgery or therapies to es-tablish their baseline. Then after the procedures, they would have a way to measure if the person was back to their prior baseline or if they were achieving the improvements. This could be espe-cially useful with treatments for frailty and func-tional problems.

Finally, Dr. Bonasera in his collaboration with colleagues, Saira Mian, Ph.D. (LLNL) and Christopher Rose, Ph.D. (Rutgers), just received a grant from the National Academy of Science. They will look at some of the mouse data he has collected over the past few years to generate a model that will enable them to understand under-lying principals of how the brain orders behaviors and how that changes as a function of aging.

Stephen Bonasera, MD, assis-tant professor of the Geriatrics/Gerontology Section, hopes to define how the brain normally ages. Unlike well-defined neurodegenerative condi-tions such as Alzheimer’s disease or Parkinson’s disease, there remains no consensus among clinicians about how the brain normally ages.

“Clinically, and from a very ba-sic science perspective, we only have a very rudimentary understanding of how the brain normally ages,” Dr. Bonasera said. By this he means what happens to the brain when it ages normally and a stroke, Alzheimer’s or other neu-rodegenerative diseases are not present.

As a geriatrician, Dr. Bonasera said he looks at changes in functional performance in the elderly rather than cognitive performance, be-cause those are the sorts of changes that can cause the elderly to enter nursing homes.

Dr. Bonasera studies this in three different ways, mostly using mouse models. He observes changes in behaviors like eating, drinking, resting and physical active in young, middle aged and old mice. He said they already have data indicat-ing the same sorts of age-related changes in basic behaviors occur in mice, as well as humans. He also looks at changes in gene expression in the brain as aging occurs. And, finally, he and col-leagues from Rutgers and the Lawrence Liver-more National Laboratories (LLNL) are develop-ing a mathematical model of these changes to see if it can provide an insight regarding how the ob-served changes in the brain contribute to these changes in behavior.

Dr. Bonasera’s laboratory focuses on how genes turn off and on in the hypothalamus of the brain. This region is thought to control behaviors like eating, drinking, and daily organization of physical activity. However, they found an inter-esting and unexpected result. They did not see

What Is Normal Aging of the Brain?

Research Briefs . . .


More Research Briefs . . .

during this study, for the first time, early childhood trauma was linked to factors associated with poor sub-stance abuse outcomes, Dr. Grant said.

Grant also has two studies in progress regarding methamphetamine dependence. One is a controlled study comparing meth addicts treated with bupropion, a drug typically used for depression or cigarette smoking cessation, to those meth addicts not receiving medica-tion for their addiction. Currently, there are approxi-mately 30 participants enrolled in this study. They hope to enroll approximately 60.

She is particularly excited about another study that is being funded by the College of Public Health. To her knowledge, no one else is studying risk or protective factors in rural meth users or rural Latino meth users. “In the lay press, methamphetamine is often portrayed as a ‘Mexican’ drug, however, almost nothing is known about rural Latino meth use,” Dr. Grant said.

This study will enroll rural and urban Latino and non-Latino meth addicts. They will look at cultural fac-tors like strong family units and ties to institutions like churches, or other community groups that may protect people from more severe meth dependency. They will also attempt to determine if there is greater risk among the large population of recent Latino immigrants in Nebraska. Additionally, a component of this study will examine HIV transmission risk factors.

Dr. Grant and research staff Ish Husain and Stepha-nie Kelley hope to enroll 190 people in this study that will be conducted at five sites in Nebraska, including three of which primarily treat Latinos.

Another group of scientists is taking a totally differ-

ent approach to the methamphetamine addiction prob-lem. The project that was conducted by UNMC scien-tists Dr. Sam Sanderson, School of Allied Health Pro-fessions; Dr. Geoff Thiele, Department of Internal Medicine; and Dr. Yuxiang Dong, Department of Phar-maceutical Sciences; and Dr. Rick Bevins, UNL, De-partment of Psychology, could be coined a basic sci-ence/translational approach.

According to UNMC Today, this group developed a vaccine that generated high quantities of anti-meth antibodies in rat models. When the meth was adminis-tered, the antibodies rapidly and effectively bound to the meth in circulation, which reduced entry of the meth to the brain. The findings suggest that the vaccine may be an important complementary method of treatment for humans when combined with standard therapies like behavior modification.

Kathleen Grant, MD, assistant professor of medicine at UNMC, and staff physician at the Substance Use Disorders Program at the Veterans Administration Nebraska/Western Iowa Health Care System, has worked on several clinical projects involving substance use disorders. Meanwhile, another team of

UNMC and UNL investigators, includ-ing Dr. Geoff Thiele, professor, Rheu-matology/Immunology Section of Internal Medicine, look at the problem of methamphetamine (meth) depend-ence from a basic science/translational perspective.

Because there is a national effort to look for safe and reasonable alterna-tives to imprisonment, the Specialized Substance Abuse Supervision (SSAS) program, an enhanced probation program for adult felony drug offenders, was created.

Dr. Grant was PI on the project funded by the Su-preme Court of Nebraska Community Corrections Council to evaluate SSAS, which was implemented in Nebraska in March 2006. Dr. Jane Meza from the College of Public Health served as a co-investigator. The program is part of the Nebraska criminal justice system’s effort to incorporate evidence-based practices that will result in better outcomes and reduce recidivism in felony drug offenders.

The project compared participants in SSAS to a matched control group of felony drug offenders sen-tenced to non-SSAS enhanced probation. According to Dr. Grant, the most consistent finding across both groups was that contingency management, essentially a reward system for specific behavior, was quite effective. Because this practice could be implemented by addic-tion therapists with various levels of training, it may be particularly useful for areas with limited access to mas-ter’s level staff.

Another of Dr. Grant’s completed studies examined trauma exposure in rural and urban veterans in treatment for substance use disorders. Veterans from rural com-munities have disproportionately served in Iraq and Af-ghanistan, Dr. Grant said.

As expected, the study revealed that rural veterans have as much trauma exposure as urban veterans. This is of particular concern because rural veterans may have less access to mental health and substance abuse (which is often co-morbid with trauma) care. Additionally,

~ Internal Medicine Investigators Participate in Substance Abuse Disorders Research ~



Once again, Dr. Ted Mikuls, associate professor of the Rheu-matology/Immunology Section, will put the Veteran’s Affairs Rheumatoid Arthritis (VARA) Registry to good use while work-ing on a recently acquired VA clinical merit review grant titled

“Impact of Genetic Variation in CD14/TLR Path-ways and Smoking in RA.” Work on the nearly one-half million dollar grant will be conducted over the next three years.

According to Dr. Mikuls, increasing data shows that cigarette smoking, associated with the risk of developing rheumatoid arthritis (RA), is also associated with health outcomes in RA. The detrimental impact of cigarette smoke in RA also appears to be increased in the presence of select genetic risk factors involved in the regulation of the immune system.

Because females compose more than two-thirds of people who suffer from RA, prior stud-ies examining the effect of smoking in RA have focused primarily on women with the disease. “This is important because smoking in terms of RA risk likely has its greatest impact in men,” Dr. Mikuls said. Moreover, men appear to suffer from a more severe form of RA than women with

the condition. For these reasons, Dr. Mikuls and his co-investigators will examine the impact of smoking in a large cohort of men with RA for this study.

Dr. Tricia LeVan, Pulmonary, Critical Care, Sleep and Allergy Medicine; Drs. Geoffrey Thiele and Alan Erickson, Rheumatology/Immunology; and Dr. Fang Yu, College of Public Health, UNMC, will serve as co-investigators on this project. These investigators will examine determinants of autoantibody production and dis-ease severity in approximately 1300 male U.S. veterans with RA and approximately 800 African Americans from the VARA and from the NIH-funded Consortium for the Longitudinal Evalua-tion of African Americans with Early RA (CLEAR) registries.

The overall hypothesis of this study, accord-ing to the investigators, is that genetic variations in CD14 and Toll-like receptors – receptors found on inflammatory cells – will mediate the detri-mental effects of smoking on RA-specific autoan-tibody production in addition to its associations with extra-articular disease (lung involvement and the development of nodules). This is impor-tant since autoantibody expression and extra-articular involvement in RA are both associated with poor disease outcomes including greater x-ray damage, disability and mortality.

Dr. Cyrus Desouza, associ-ate professor, Diabetes, Endocri-nology & Metabolism Section, recently received a three-year VA merit review grant to further his research on the role apathy plays in patients with uncontrolled dia-betes. Apathy is described as a

lack of motivation and persistence. Motivation and persistence are traits necessary in order to achieve good diabetes control, according to Dr. Desouza.

Desouza has preliminary data that showed a correlation between patients with uncontrolled diabetes and apathy. According to data from one previous study, apathetic patients were nearly

three times more likely than those without apathy to be impaired in day-to-day activities.

“Apathy can be devastating for patients with diabetes,” Dr. Desouza said. “Once they loose interest and stop managing the disease, the health ramifications can be dramatic.”

Dr. Desouza hopes to enroll about 100 VA patients in this project. To treat the apathy, pa-tients will be given methylphenidate, a compound that is commonly used to slow hyperactivity in children. It has also previously been shown to treat apathy. In adults with apathy, it is believed to give them more energy by increasing dopamine levels in the brain. Patients will be monitored for actual improvements in their diabetes control in terms of HbA1c and blood pressure.


In the News . . .

In March, the University and the Department of Internal Medicine lost a wonder-ful friend, Robert Grissom, MD, who served in various capacities at UNMC from 1953 to 1987. Dr. Grissom was not only known for his service as a physician, teacher and mentor and administrator, but also for his gentle, caring and dignified demeanor.

He held many leadership positions at the university and locally. He was appointed the first full-time chairman of the Department of Internal Medicine in 1956. He was president of the UNMC Faculty Senate, president of Alpha Omega Alpha, president of the Nebraska Chapter of the American Heart Association, as well as of the Ameri-can Lung Association. Even after his retirement in 1987, he continued to teach and volunteer his time reading slides at the VA Medical Center as an emeritus faculty

member. In 1999, he received the Dean’s Award for Distinguished Service to the College of Medicine. Some of his former students and colleagues called him the most considerate, dependable, genuine and

honorable person they had ever known. Many who knew him, thought him to be a supportive, helpful and kind colleague. One colleague said he was respected and honored by all – his patients, students, colleagues and friends.

Dr. James O’Dell, profes-sor and chief of the Rheuma-tology/Immunology Section, is leading a task force of the American College of Rheu-matology to take a currently existing mini-registry and evolve it into a full fledged

rheumatology registry . Many factors lead to the need for this, including but not limited to: clini-cians being asked to document their quality of care but with different measures by different pay-ers, third-party payers trying to define and recog-nize what a quality practice is but by different measures, the FDA requiring post-marketing sur-veillance of products, and the government asking

for comparative effectiveness studies. The regis-try would help rheumatology practices document many issues of interest.

This is a huge project that is being addressed in stages, Dr. O’Dell said. Ultimately, it is the hope that the majority of rheumatologists and rheumatology practices will be participating in the program. They envision the participants’ electronic medical records dumping data into this giant rheumatic database.

Currently, meetings are being conducted with interested parties on a national and interna-tional level to discuss standardizing nomencla-ture and data fields for rheumatic disease. The initial module documents quality. Three more modules will be rolling out in a month or so, and there are at least a dozen modules anticipated.

The program is being tested among a small group of practices initially, and others will be added in a pyramid fashion. Right now, ACR is underwriting the infrastructure. However, they expect to charge some fee to participants when the test period is complete. Working out the business plan is another of the duties of the task force, Dr. O’Dell said.

It will be useful for:

Documentation of quality measures

Documenting patient visits

Coding

Comparative effectiveness

Documentation of practice excellence

Research purposes

Recertification tracking



Education Highlights . . .

2010-2011 Chief Residents Announced

Chad Reade Eric Rome Rebecca Runge

2009-2010 Chief Residents

Matthew A. Lunning, DO, will serve as the Internal Medicine chief resident for UNMC. Dr. Lun-ning is a graduate of Des Moines University College of Osteopathic Medicine and began his Internal Medicine Residency here in July 2006.

In the summer of 1999, Dr. Lunning participated in a summer internship at Mercy Cancer Center in Mason City, Iowa. He also partici-pated in a Food and Drug Administration summer in-ternship three years, during the summers of 2000, 2001 and 2002. His research on lymphocyte cell mor-

phology during 2001 led to submission and accep-tance of an abstract to both a national meeting and an international meeting. At the conclusion of the third summer, an article titled “Albumin Enhanced Mor-phometric Image Analysis in CLL,” was submitted to the journal Cytometry.

Dr. Lunning has given 13 presentations since 1999, and he is first author on three articles published in peer reviewed journals. Dr. Lunning also received the North Iowa Area Community College, Christo-pherson Medical Scholarship; the Clinical Cytometry Society’s 1st Annual Janis Giorgi Young Investigator Award; and the International Society for Analytical Cytometry Student Investigator Award.

Andrew Vasey, MD, will serve as the chief resident at the VA. Dr. Vasey received his medical degree from UNMC.

As an undergraduate at Ne-braska Wesleyan University, he was a member of the Beta Beta Beta Biology Honor Society, and in

2000, he received a Howard Hughes Medical Institute Research Grant. His project was regarding the effects of 5-azacytidine on replication of Chlorella viruses and selection of 5-azacytidine resistant mutants.

He was the Vice President, Community Relations of the Blue Key National Honor Fraternity, a member of the Alpha Mu Gamma Foreign Language Honor Society and a NAIA All-American Scholar Athlete.

In medical school he was President, Club Med (Internal Medicine Interest Group), a member of the American Medical Association, the Nebraska Medical Association and a student member of the ACP.

In 2008, he presented a poster at the Nebraska Chapter ACP meeting titled "Stress-induced cardio-myopathy in a twenty-two year old female." He is an associate member of the ACP and a member of the Society of General and Internal Medicine.

Keely Hack, MD, will serve as the ambulatory chief resident. Dr. Hack received her medical degree from Sanford School of Medicine at the University of South Dakota and began her residency in internal medicine at UNMC in 2006.

She graduated Magna Cum Laude from her undergraduate institution, Mount Marty College in Yankton, S.D., where she was also a member of Lambda Delta Lambda. During medical school, she participated in a six-week program in a rural South Dakota community where she participated in patient care with a primary care physician. In medi-cal school, she also completed a two-week elective in internal medicine in the rural mountains of Bolivia.

Her research experience includes a project during medical school assessing South Dakotan’s perception of stroke risk factors and warning signs. In her second year in residency, she began working on a project looking at the effect of diabetes mellitus on the epide-miology of lung cancer. Dr. Hack presented this work at the Nebraska American College of Physicians (ACP) Annual Chapter Meeting in 2008, submitted an abstract to the International Association for the Study of Lung Cancer’s 13th World Conference, and is in the process of preparing a manuscript for publication. Dr. Hack is also currently working on a review article regarding lung cancer in non-smokers.

During her residency, Dr. Hack participated in a program with the electronic medical records system to assist residents with centralized tracking of health maintenance information.


New Grant Awards

#2118 (Industry; Millennium Pharmaceuticals, Inc; PI is Vose) An open-label, phase 1 study of MLN8237, a novel Aurora a kinase inhibitor, in patients with advanced hemato-logical malignancies. 1/19/2009-1/18/2010 (Year 1) Direct Costs: $67,852.

#2128 (Intramural; Eppley; PI is McKeithan) Chromatin Structure of Genes Important in B-Cell Lymphoma and Multiple Myeloma. 3/5/2009-8/31/2009 (Year 1) Direct Costs: $50,000.

#2140 (Industry; Abbott Cardiovascular Systems, Inc.; PI is Shurmur) XIENCE V Ever-olimus Eluting Coronary Sent System (EECSS) EXCEED. 2/24/2009-2/23/2010 (Year 1) Direct Costs: $21,081.

#2141 (Industry; AstraZeneca LP; PI is O'Leary) A 104-Week, Randomized, Double-Blind, Parallel Arm, Multi-Center Phase IIIb Study Comparing the Effects of Treatment with Rosuvastatin 40mg or Atorwas-tatin 80 mg on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Patients with Coronary Artery Disease who Require Coronary Angiography. 2/25/2009-2/24/2010 (Year 1) Direct Costs: $217,873.

#2142 (Other-Extramural; Northwestern University; PI is McCashland) Interferon-Induced Graft Dysfunc-tion after Liver Transplantation: A Multicenter Case Control Study. 1/1/2009-12/31/2009 (Year 1) Direct Costs: $3,984.

#2143 (Industry; Bristol-Myers Squibb Pharmaceuticals; PI is VanSchooneveld) Validation of a Dried Blood Spot Assay for Atazanavir. 1/20/2009-1/19/2010 (Year 1) Direct Costs: $14,929.

#2144 (Industry; Molnlycke Health Care US, LLC; PI is Rupp) Effectiveness of Chlorhexide Gluconate (CHG) Tathing to Reduce Occurrence of Catheter-Associated Bloodstream Infections and Transmission and/or Infection Due to Multi-Drug Resistant Organisms in Hospitalized Patients. 2/4/2009-2/3/2010 (Year 1) Direct Costs: $95,651.

#2151 (Industry; Actelion Pharmaceuticals, Ltd.; PI is Thompson) A multicenter-double-blind, random-ized, placebo-controlled, parallel group, event-driven phase III study to assess the effects of ACT-064992 on morbidity and mortality in patients with symptomatic pulmonary arterial hypertension. 3/24/2009-3/23/2010 (Year 1) Direct Costs: $39,173.

#2152 (Industry; Actelion Pharmaceuticals, Ltd.; PI is Thompson) Long-Term Single-Arm Open-Label Extension Study of SERAPHIN Study, to Assess the Safety and Tolerability of ACT-064992 in Patients with Symptomatic Pulmonary Arterial Hypertension. 3/16/2009-3/15/2010 (Year 1) Direct Costs: $6,917.

#2159 (Industry; Hana Biosciences, Inc.; PI is Devetten) A Phase 2 Study to Evaluate the Safety and Effi-cacy of Weekly Doses of Marqibo (Vincristine Sulfate Liposomes Injection) in Adult Patients with Phila-delphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Pa-tients with Philadelphia Chromosome-negative ALL who Failed Two Treatment Lines of Anti-leukemia Chemotherapy. 1/26/2009-1/25/2010 (Year 1) Direct Costs: $31,313.

#2160 (Industry; Rigel Pharmaceuticals, Inc.; PI is Vose) Phase II, Multicenter, Simon Two-Stage Study of R788 in Patients with Relapsed or Refractory T-cell Lymphoma. 1/8/2009-1/7/2010 (Year 1) Direct Costs: $39,266.

Internal Medicine Grant Activity 1st Quarter 2009


Internal Medicine Grant Activity (continued ) 1st Quarter 2009 #2162 (Industry; Novartis Pharmaceuticals, Inc.; PI is Kessinger) An Open-Label, Multi-Center, Expanded Access Study of RAD001 in Patients with Metastatic Carcinoma of the Kidney who have Progressed De-spite Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. 2/12/2009-1/11/2010 (Year 1) Direct Costs: $39,752.

#2163 (Industry; Novartis Pharmaceuticals, Inc.; PI is Ganti) A Phase III, Randomized, Double-Blind, Pla-cebo-Controlled Multi-Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC). 2/24/2009-2/23/2010 (Year 1) Direct Costs: $40,533.

#2164 (Other-Extramural; National Marrow Donor Program; PI is Vose) A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Pateints with Hematologic Malignancies. 1/1/2009-12/31/2009 (Year 1) Direct Costs: $11,238.

#2167 (Industry; Otsuka Maryland Research Institute, Inc.; PI is Rennard) A multicenter, randomizedm dou-ble-blind, placebo-controlled pilot study to assess the pharmacodynamics, efficacy, and safety of 50mg te-tomilast administered as oral tablest in patients with emphysema associated with chronic obstructive pulmo-nary disease . 1/1/2009-12/31/2009 (Year 1) Direct Costs: $117,693.

Other Ongoing Grant Awards:

NIH Investigator-Initiated Grant Awards #962 (PI is Casey) Effects of ethanol on endocytosis in the liver (R01) (competitive renewal of grant key #374). 1/1/2009-12/31/2009 (Year 6) Direct Costs: $.

#1495 (NIAAA; PI is McVicker) Alcohol & FAS mediated apoptosis in polarized liver cells. 2/1/2009-1/31/2010 (Year 4) Direct Costs: $103,199.

#1735 (NIAAA; PI is Thiele) Alcohol and Liver Endothelial Cells in Immune Responses. 2/1/2009-1/31/2010 (Year 13) Direct Costs: $202,500.

NIH Sub-Contracted

#1254 (NIAID; PI is Freifeld) Investigation of the natural history of West Nile Virus infection in patients with or at risk for progression to West Nile Virus Encephalitis and/or Myelitis (CASG #211) (DMID #03-114). 3/15/2009-3/14/2010 (Year 5) Direct Costs: $22,968.

#1163 (NCI; PI is Vose) APhase I/II Trial of VELCADE + CHOP-Rituximab in Patients with Previously Untreated Diffuse Large B Cell or Mantle Cell Non-Hodgkins Lymphoma (NHL). 1/1/2009-12/31/2009 (Year 6) Direct Costs: $.

Other Extramural #1920 (National Marrow Donor Program; PI is Vose) A Phase III, Randomized Double-Blind, Placebo-Controlled Trial of Solubel Tumor Necrosis Factor Receptor: Enbrel for the Treatment of Acute Non-Infectious Pulmonary Dysfunction Following Allogeneic Cell Transplantation. 3/1/2009-3/31/2009 (Year 3) Direct Costs: $.

#1446 (Oxford University, UK; PI is Plumb) SHARP Study (Study of Heart and Renal Protection). 3/1/2009-2/28/2010 (Year 5) Direct Costs: $.

#1736 (American Heart Association; PI is Anderson) Detection and monitoring of vascular inflammatory events. 1/1/2009-12/31/2009 (Year 3) Direct Costs: $59,091.


#1833 (Duke University Medical Center; PI is Freifeld) Transplant Infection Network. 3/16/2009-3/16/2010 (Year 3) Direct Costs: $. #2112 (National Marrow Donor Program; PI is Vose) A phase II study of allogeneic transplant for older pa-tients with AML in first morphologic complete remission using a non-myeloablative preparative regimen. 1/22/2009-12/31/2009 (Year 3) Direct Costs: $.

#922 (North American Rheumatoid Arthritis Consortium; PI is O'Dell) The genetics of rheumatoid arthritis. 1/1/2009-12/31/2009 (Year 7) Direct Costs: $.

#1506 (National Marrow Donor Program; PI is Vose) Initial systemic treatment of acute GVHD: A phase II randomized trial evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in combination with corticosteroids. 2/1/2009-1/31/2010 (Year 5) Direct Costs: $.

Industry Grant Awards #1676 (GlaxoSmithKline; PI is Rennard) A multicenter 3 year longitudinal prospective study to identify novel endpoints and compare these with forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD severity and its progression over time SCO104960-ECLIPSE. 3/6/2009-3/5/2010 (Year 4) Direct Costs: $.

#1878 (Roche Laboratories, Inc.; PI is Rennard) A Double-blind, placebo-controlled efficacy (as assessed by post bronchodilator FEV1) and safety of 5 mg RO3300074 once daily for 2 years in subjects with smok-ing-related moderate to severe COPD with emphysema receiving concurrent optimal COPD drug therapy. 3/22/2009-10/9/2009 (Year 3) Direct Costs: $.

#1599 (Vical Incorporated; PI is Freifeld) A phase 2 clinical trial to evaluate the safety, immunogenicity, and clinical benefit of a CMV immunotherapeutic vaccine in donors and CMV-seropositive recipients un-dergoing allogeneic, matched related hematopoietic cell transplant (HCT). 1/1/2009-8/31/2009 (Year 4) Di-rect Costs: $.

#2001 (AstraZeneca Pharmaceuticals; PI is Rennard) Synergistic effects of budesonide and formoterol in the regulation of connective tissue synthesis via MMP and PGE mediated pathways. 2/24/2009-2/28/2009 (Year 2) Direct Costs: $87,880.

#1783 (Sanofi Aventis; PI is McCashland) Satavaptan in the prevention of ascites recurrence: a double-blind, randomized, parallel-group comparison of satavaptan at 5 to 10 mg daily versus placebo in the ab-sence of diuretics in patients with recurrent ascites due to cirrhosis of the liver. 2/1/2009-3/31/2009 (Year 3) Direct Costs: $.

#1818 (Sanofi Aventis; PI is McCashland) Satavaptan cirrhotic ascites treatment study: a double blind ran-domized parallel group comparison of treatment wi/ satavaptan at 5 to 10 mg daily vs placebo on top of con-ventional treatment in patients with ascites due to cirrhosis of the liver. 1/1/2009-1/31/2009 (Year 3) Direct Costs: $.

#2027 (Eisai Medical Research, Inc. ; PI is Kalil) ACCESS: A controlled comparison of Eritoran Tetraso-dium and placebo in pateints with severe sepsis. 2/1/2009-1/31/2010 (Year 2) Direct Costs: $.

#1883 (Gentium; PI is Devetten) Defibrotide for the treatment of severe hepatic veno-occlusive disease in HSCT patients: A historically-controlled, multi-center phase 3 study to determine safety and efficacy. 1/15/2009-12/31/2009 (Year 3) Direct Costs: $.

Internal Medicine Grant Activity (continued ) 1st Quarter 2009


Internal Medicine Grant Activity (continued ) 1st Quarter 2009

#1597 (Bristol-Myers Squibb Pharmaceuticals; PI is Devetten) A randomized, two-by-two, multicenter, open-label phase III study of BMS-354825 administered orally at a dose of 50 mg or 70 mg twice daily or 140 mg once daily in subjects with chronic phase Philadelphia Chromosome or BCR-ABL positive chronic myelogenous leukemia who are resistant or intolerant to Imatinib Mesylate (Gleevec). 1/5/2009-11/30/2009 (Year 4) Direct Costs: $.

#1595 (Bristol-Myers Squibb Pharmaceuticals; PI is Devetten) A randomized, two-arm, multicenter, open-label phase II study of BMS-354825 administered orally ... in subjects with chronic myeloid leukemia in accelerated phase or in myeloid or lymphoid blast phase or with Philadelphia chromosome positive acute lymphoblastic leukemia who are resistant or intolerant to Imatinib Mesylate (Gleevac). 1/6/2009-11/30/2009 (Year 4) Direct Costs: $.

#1265 (Pfizer, Inc.; PI is Swindells) A multicenter, randomized, double-blind, comparative trial of novel CCR5 antagonist, UK-427,857, in combination with Zidovudine/Lamivudine versus Efavirenz in combina-tion with Zidovudine/Lamivudine for the treatment of antiretroviral-naive, HIV-1 infected subjects (#A4001026). 3/9/2009-3/8/2010 (Year 5) Direct Costs: $.

#1607 (Pfizer, Inc.; PI is Swindells) A multicenter, randomized, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857, in combination with optimized background therapy versus optimized background therapy alone for the treatment of antiretroviral-experienced HIV-1 infected subjects. 3/9/2009-3/8/2010 (Year 5) Direct Costs: $.

#2023 (Bavarian Nordic GmbH; PI is Swindells) A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects with CD4 Counts >/= 200 - 500/microliters. 1/23/2009-6/30/2009 (Year 2) Direct Costs: $.

#1846 (Amgen, Inc.; PI is Plumb) EVOLVE: Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events. 2/8/2009-2/7/2010 (Year 3) Direct Costs: $.

Administered By Other Department #1815 (St. Jude Medical; PI is Anderson) OPTIMUM Lead Insulation Material Registry. 2/26/2009-2/25/2010 (Year 3) Direct Costs: $.

$. If no dollars were included, all funds were allocated to the first year the grant was active.


PubMed#, Authors, Manuscript or Chapter Title, Book Title, Journal Short Name, Volume, Issue, Pages, Year

19399804, Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT, National Institutes of Health consensus development conference statement: Management of hepatitis B., Hepatology (Baltimore, Md.), Hepatology, 49, S5, S4-S12, 2009

19395665, Poole JA, Wyatt TA, Oldenburg PJ, Elliott MK, West WW, Sisson JH, Von Essen SG, Romberger DJ, Intranasal Organic Dust Exposure-Induced Airway Adaptation Response Marked By Per-sistent Lung Inflammation and Pathology in Mice., American journal of physiology. Lung cellular and mo-lecular physiology, Am. J. Physiol. Lung Cell Mol. Physiol., 2009

19376194, Curry-McCoy TV, Osna NA, Donohue TM, Modulation of Lysozyme Function and Deg-radation after Nitration with Peroxynitrite., Biochimica et biophysica acta, Biochim. Biophys. Acta, 2009

19355405, Unger E, Matsunaga T, Xie F, Porter T, Diagnostic ultrasound combined with targeted microbubbles improves recovery following acute coronary thrombosis., The Journal of the Acoustical Soci-ety of America, J. Acoust. Soc. Am., 125, 4, 2713, 2009

19185565, Dalton SR, Lee SM, King RN, Nanji AA, Kharbanda KK, Casey CA, McVicker BL, Carbon tetrachloride-induced liver damage in asialoglycoprotein receptor-deficient mice., Biochemical phar-macology, Biochem. Pharmacol., 77, 7, 1283-90, 2009

19139290, Freifeld A, Proia L, Andes D, Baddour LM, Blair J, Spellberg B, Arnold S, Lentnek A, Wheat LJ, Voriconazole use for endemic fungal infections., Antimicrobial agents and chemotherapy, Antim-icrob. Agents Chemother., 53, 4, 1648-51, 2009

19135063, Pienaar E, Whitney SE, Viljoen HJ, van Rensburg NF, A model of the complex response of Staphylococcus aureus to methicillin., Journal of theoretical biology, J. Theor. Biol., 257, 3, 438-45, 2009

19239903, Kharbanda KK, Vigneswara V, McVicker BL, Newlaczyl AU, Bailey K, Tuma D, Ray DE, Carter WG, Proteomics reveal a concerted upregulation of methionine metabolic pathway enzymes, and downregulation of carbonic anhydrase-III, in betaine supplemented ethanol-fed rats., Biochemical and bio-physical research communications, Biochem. Biophys. Res. Commun., 2009

19235011, Armitage JO, Cancer care--the relation between resources and outcome., Leukemia & lymphoma, Leuk. Lymphoma, 50, 2, 152-3, 2009

P, 19228653, Wolfe F, Michaud K, Outcome and Predictor Relationships in Fibromyalgia and Rheu-matoid Arthritis: Evidence Concerning the Continuum versus Discrete Disorder Hypothesis., The Journal of rheumatology, J. Rheumatol., 2009

19219625, Kharbanda KK, Todero SL, Ward BW, Cannella JJ, Tuma DJ, Betaine administration corrects ethanol-induced defective VLDL secretion., Molecular and cellular biochemistry, Mol. Cell. Bio-chem., 2009

19204203, Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK, Follicular Lymphoma in the United States: First Report of the National LymphoCare Study., Journal of clinical oncology : official journal of the Ameri-can Society of Clinical Oncology, J. Clin. Oncol., 2009

19191590, Wilkin TJ, McKinnon JE, Dirienzo AG, Mollan K, Fletcher CV, Margolis DM, Bastow B, Thal G, Woodward W, Godfrey C, Wiegand A, Maldarelli F, Palmer S, Coffin JM, Mellors JW, Swindells S, Regimen Simplification to Atazanavir-Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48-Week Clinical and Virologic Outcomes., The Journal of infectious diseases, J. Infect. Dis., 2009

Internal Medicine Faculty Publications: Jan - April 2009


19190306, Kang LY, A piece of my mind. The first wake., JAMA : the journal of the American Medi-cal Association, JAMA, 301, 5, 467-8, 2009

19167348, Liu X, Nelson A, Wang X, Kanaji N, Kim M, Sato T, Nakanishi M, Li Y, Sun J, Michalski J, Patil A, Basma H, Rennard SI, MicroRNA-146a modulates human bronchial epithelial cell survival in response to the cytokine-induced apoptosis., Biochemical and biophysical research communications, Bio-chem. Biophys. Res. Commun., 380, 1, 177-82, 2009

19125135, Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR, The effect of serum urate on gout flares and their associated costs: an administrative claims analysis., Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, J Clin Rheumatol, 15, 1, 3-7, 2009

19061424, Hopkins WJ, Elkahwaji J, Kendziorski C, Moser AR, Briggs PM, Suhs KA, Quantitative trait loci associated with susceptibility to bladder and kidney infections induced by Escherichia coli in fe-male C3H/HeJ mice., The Journal of infectious diseases, J. Infect. Dis., 199, 3, 355-61, 2009

19055670, Abuzetun JY, Loberiza F, Vose J, Bierman P, Bociek RG, Enke C, Bast M, Weisen-burger D, Armitage JO, Nebraska Lymphoma Study Group , The Stanford V regimen is effective in pa-tients with good risk Hodgkin lymphoma but radiotherapy is a necessary component., British journal of hae-matology, Br. J. Haematol., 144, 4, 531-7, 2009

19010609, Reichel CM, Murray JE, Grant KM, Bevins RA, Bupropion attenuates methamphetamine self-administration in adult male rats., Drug and alcohol dependence, , 100, 1-2, 54-62, 2009

18795378, Goldner WS, Stoner JA, Lyden E, Thompson J, Taylor K, Larson L, Erickson J, McBride C, Finding the Optimal Dose of Vitamin D Following Roux-en-Y Gastric Bypass: A Prospective, Random-ized Pilot Clinical Trial., Obesity surgery, , 19, 2, 173-9, 2009

1000000303, Hermsen ED, Shull SS, Mitropoulos IF, Puumala SE, Rupp ME, Prospective evaluation of clinical and economic outcomes associated with treatment of serious infectious due to gram-positive co, Infectious Diseases in Clinical Practice, 17, 1, 17-21, 2009

19343296, Armitage JO, Targeted therapy and hematological malignancy., Targeted oncology, Tar-get Oncol, 4, 1, 1-2, 2009

19183138, Sisson JH, Pavlik JA, Wyatt TA, Alcohol Stimulates Ciliary Motility of Isolated Airway Axonemes Through a Nitric Oxide, Cyclase, and Cyclic Nucleotide-Dependent Kinase Mechanism., Alco-holism, clinical and experimental research, Alcohol. Clin. Exp. Res., 2009

19176207, Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, De-metri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK, Myeloid growth factors., Journal of the National Comprehensive Cancer Network : JNCCN, , 7, 1, 64-83, 2009

19155139, Avery EJ, Kessinger A, Ganti AK, Therapeutic options for elderly patients with advanced non-small cell lung cancer., Cancer treatment reviews, Cancer Treat. Rev., 2009

19135949, Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, An-derlini P, Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma., Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, Biol. Blood Marrow Transplant., 15, 1, 109-17, 2009

19124811, Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT, National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B., Annals of internal medicine, Ann. Intern. Med., 2009

IM Faculty Publications (continued) Jan - April 2009


IM Faculty Publications (continued) Jan - April 2009 19112327, O'Grady NP, Kalil A, Barie P, Bleck T, Misguided guidelines on noninvasive thermome-

try., Critical care medicine, Crit. Care Med., 37, 1, 383-384, 2009

19067662, Raichlin E, Villarraga HR, Chandrasekaran K, Clavell AL, Frantz RP, Kushwaha SS, Rodeheffer RJ, McGregor CG, Daly RC, Park SJ, Kremers WK, Edwards BS, Pereira NL, Cardiac al-lograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality., American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, Am. J. Transplant., 9, 1, 132-9, 2009

19058754, Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P, Metroticket Inve , Predicting survival after liver transplantation in pa-tients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis., The lancet oncology, Lancet Oncol., 10, 1, 35-43, 2009

19040313, Wolfe F, Michaud K, Proposed metrics for the determination of rheumatoid arthritis out-come and treatment success and failure., The Journal of rheumatology, J. Rheumatol., 36, 1, 27-33, 2009

19008338, Harrison-Findik DD, Klein E, Evans J, Gollan J, Regulation of liver hepcidin expression by alcohol in vivo does not involve Kupffer cell activation or TNF-{alpha} signaling., American journal of physiology. Gastrointestinal and liver physiology, Am. J. Physiol. Gastrointest. Liver Physiol., 296, 1, G112-8, 2009

18931055, Oldenburg PJ, Wyatt TA, Factor PH, Sisson JH, Alcohol feeding blocks methacholine-induced airway responsiveness in mice., American journal of physiology. Lung cellular and molecular physiology, Am. J. Physiol. Lung Cell Mol. Physiol., 296, 1, L109-14, 2009

18848647, Mikuls TR, Payne JB, Reinhardt RA, Thiele GM, Maziarz E, Cannella AC, Holers VM, Kuhn KA, O'Dell JR, Antibody responses to Porphyromonas gingivalis (P. gingivalis) in subjects with rheumatoid arthritis and periodontitis., International immunopharmacology, Int. Immunopharmacol., 9, 1, 38-42, 2009

18828798, Sykora P, Kharbanda KK, Crumm SE, Cahill A, S-adenosyl-L-methionine co-administration prevents the ethanol-elicited dissociation of hepatic mitochondrial ribosomes in male rats., Alcoholism, clinical and experimental research, Alcohol. Clin. Exp. Res., 33, 1, 1-9, 2009

18798849, Florescu DF, Iwen PC, Hill LA, Dumitru I, Quader MA, Kalil AC, Freifeld AG, Cere-bral aspergillosis caused by Aspergillus ustus following orthotopic heart transplantation: case report and review of the literature., Clinical transplantation, , 23, 1, 116-20, 2009

18573566, Ganti AK, Loberiza FR, Kessinger A, Association of positive family history with sur-vival of patients with lung cancer., Lung cancer (Amsterdam, Netherlands), Lung Cancer, 63, 1, 136-9, 2009

19332634, Wolfe F, Boers M, Felson D, Michaud K, Wells GA, Remission in Rheumatoid Arthritis: Physician and Patient Perspectives., The Journal of rheumatology, J. Rheumatol., 2009

19328860, Florescu DF, Murphy PJ, Kalil AC, Effects of Prolonged Use of Azithromycin in Patients with Cystic Fibrosis: A Meta-Analysis., Pulmonary pharmacology & therapeutics, 2009

19325896, Osna NA, Alcohol and liver., World journal of gastroenterology : WJG, World J. Gastro-enterol., 15, 10, 1162, 2009

19298329, Allen-Gipson DS, Jarrell JC, Bailey KL, Robinson JE, Kharbanda KK, Sisson JH, Wyatt TA, Ethanol Blocks Adenosine Uptake via Inhibiting the Nucleoside Transport System in Bronchial Epithelial Cells., Alcoholism, clinical and experimental research, Alcohol. Clin. Exp. Res., 2009


19291821, Schaffert CS, Duryee MJ, Hunter CD, Hamilton BC, Deveney AL, Huerter MM, Klassen LW, Thiele GM, Alcohol metabolites and lipopolysaccharide: Roles in the development and/or progres-sion of alcoholic liver disease., World journal of gastroenterology : WJG, World J. Gastroenterol., 15, 10, 1209-18, 2009

19291820, Osna NA, Hepatitis C virus and ethanol alter antigen presentation in liver cells., World journal of gastroenterology : WJG, World J. Gastroenterol., 15, 10, 1201-8, 2009

19291819, Lee SM, Casey CA, McVicker BL, Impact of asialoglycoprotein receptor deficiency on the development of liver injury., World journal of gastroenterology : WJG, World J. Gastroenterol., 15, 10, 1194-200, 2009

19291818, Harrison-Findik DD, Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease?, World journal of gastroenterology : WJG, World J. Gastroenterol., 15, 10, 1186-93, 2009

19291817, Donohue TM, Autophagy and ethanol-induced liver injury., World journal of gastroen-terology : WJG, World J. Gastroenterol., 15, 10, 1178-85, 2009

19286844, Feser M, Derber LA, Deane KD, Lezotte DC, Weisman MH, Buckner JH, Mikuls T, O'Dell J, Gregersen PK, Holers VM, Norris JM, Plasma 25,OH Vitamin D Concentrations Are Not Associ-ated with Rheumatoid Arthritis (RA)-related Autoantibodies in Individuals at Elevated Risk for RA., The Journal of rheumatology, J. Rheumatol., 2009

19283845, Aldoss IT, Plumb T, Zhen WK, Lydiatt DD, Ganti AK, Cetuximab in hemodialysis: A case report., Head & neck, Head Neck, 2009

19255341, Xie F, Lof J, Matsunaga T, Zutshi R, Porter TR, Diagnostic Ultrasound Combined With Glycoprotein IIb/IIIa-Targeted Microbubbles Improves Microvascular Recovery After Acute Coronary Thrombotic Occlusions., Circulation, Circulation, 2009

19212311, Mukherjee S, Mahmoudi TM, Mukherjee U, Liver transplant for viral hepatitis and fulmi-nant hepatic failure., Minerva gastroenterologica e dietologica, , 55, 1, 83-100, 2009

19207079, Cosgrove SE, Vigliani GA, Fowler VG, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW, Initial low-dose gentamicin for Staphylococcus aureus bac-teremia and endocarditis is nephrotoxic., Clinical infectious diseases : an official publication of the Infec-tious Diseases Society of America, Clin. Infect. Dis., 48, 6, 713-21, 2009

19199534, Kanafani ZA, Arduino JM, Muhlbaier LH, Kaye KS, Allen KB, Carmeli Y, Corey GR, Cosgrove SE, Fraser TG, Harris AD, Karchmer AW, Lautenbach E, Rupp ME, Peterson ED, Straus WL, Fowler VG, Incidence of and preoperative risk factors for Staphylococcus aureus bacteremia and chest wound infection after cardiac surgery., Infection control and hospital epidemiology: the official journal of the Society of Hospital Epidemiologists of America, , 30, 3, 242-8, 2009

19154729, Cordes CM, Bennett RG, Siford GL, Hamel FG, Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation., Biochemical pharmacology, Biochem. Pharmacol., 77, 6, 1064-73, 2009

19135917, Rogers KL, Fey PD, Rupp ME, Coagulase-negative staphylococcal infections., Infectious disease clinics of North America, Infect. Dis. Clin. North Am., 23, 1, 73-98, 2009

19120068, Bailey KL, Wyatt TA, Romberger DJ, Sisson JH, Alcohol functionally upregulates Toll-like receptor 2 in airway epithelial cells., Alcoholism, clinical and experimental research, Alcohol. Clin. Exp. Res., 33, 3, 499-504, 2009

IM Faculty Publications (continued) Jan - April 2009

Internal Medicine

Department of Internal Medicine 983332 Nebraska Medical Center

Omaha, NE 68198-3332

Selaba Travis Phone: 402-559-4875

Fax: 402-559-6114 Email: [email protected]

Health care that's changing our world!

The University of Nebraska Medical Center, Nebraska’s academic health

science center, is recognized nationally and internationally as a leader in

research, education and patient care. Success in patient care grows from UNMC’s

pioneering efforts in basic science and clinical research. UNMC is the only public

health science center in the state. Its educational programs are responsible for

training more health professionals practicing in Nebraska than any other

institution.

Through its commitment to education, research, patient care, and outreach,

UNMC has established itself as one of the country's leading centers for research

in cancer, transplantation biology, robotic surgery, neurosciences, nanomedicine,

biosecurity and arthritis. UNMC’s research funding from external sources is now

nearly $80 million annually, and has resulted in the creation of more than 2,600

highly skilled jobs in the state.

Research is an integral part of UNMC’s academic medical center. Research

demands an inquisitive mind, the ability to apply scientific principles and a certain

intellectual rigor that is mandatory for education. For more information about

research in the Department of Internal Medicine, contact Selaba Travis, Research

Support Office at: (402) 559-4875; email: [email protected]

W E’ R E O N T H E W E B A T: w w w . u n m c . e d u / i n t m e d /

UNMC Internal Medicine research news items, announcements, grant awards and applications, publications, presentations, appointments, etc., can be sent at any time to:

Selaba Travis, Department of IM, UNMC, Campus Zip 3332, x4875, [email protected]

The UNMC Department of Internal Medicine Newsletter is published quarterly for the Internal Medicine faculty, staff, fellows, residents, and students.

Health care that’s changing our world!

The UNMC Department of Internal Medicine Newsletter is published quarterly for the Internal Medicine faculty, staff, fellows, residents, and students.

Health care that’s changing our world!

department of internal medicine - unmc | home

Documents